Low impact
AstraZeneca and Daiichi are near a UK price deal for a breast cancer drug, potentially providing access to women in England and Wales with a certain type of breast cancer.
bloomberg-industries07/08, 06:11 PM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.